Absorption and Clearance of Pharmaceutical Aerosols in the Human Nose: Development of a CFD Model

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 29, Issue 5, 2016, Pages 416-431

  Rygg, Alex ^a   Longest, P Worth ^a,b  

^a Virginia Commonwealth University   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Dosimetry Modeling; Drug Particle Dissolution; Microdosimetry; Nasal Clearance; Nasal Drug Absorption; Nasal Spray Suspensions; Post Deposition Particle Tracking

Indexed keywords

MOMETASONE FUROATE;

ACCURACY; AEROSOL; ALGORITHM; ARTICLE; CALCULATION; COMPUTATIONAL FLUID DYNAMICS; DRUG ABSORPTION; DRUG DETERMINATION; DRUG SOLUBILITY; DRUG UPTAKE; GEOMETRY; MATHEMATICAL MODEL; MUCOCILIARY CLEARANCE; NOSE CAVITY; PREDICTION; SENSITIVITY ANALYSIS; SIMULATION;

EID: 84989815745     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2015.1252     Document Type: Article

References (75)

1. Costantino HR, Illum L, Brandt G, Johnson PH, and Quay SC: Intranasal delivery: Physicochemical and therapeutic aspects. Intl J Pharma. 2007;337:1-24.
2. Hussain AA: Intranasal drug delivery. Adv Drug Deliv Rev. 1998;29:39-49.
3. Turker S, Onur E, and Ozer Y: Nasal route and drug delivery systems. Pharma World Sci. 2004;26:137-142.
4. Arora P, Sharma S, and Garg S: Permeability issues in nasal drug delivery. Drug Discov Today. 2002;7:967-975.
5. Illum L: Nasal drug delivery: New developments and strategies. Drug Discov Today. 2002;7:1184-1189.
6. Suman JD, Laube BL, and Dalby R: Comparison of nasal deposition and clearance of aerosol generated by a nebulizer and an aqueous spray pump. Pharma Res. 1999;16:1648-1652.
7. Laube BL: Devices for aerosol delivery to treat sinusitis. J Aerosol Med. 2007;20:S5-S18.
8. Liu Y, Matida EA, and Johnson MR: Experimental measurements and computational modeling of aerosol deposition in the Carleton-Civic standardized human nasal cavity. J Aerosol Sci. 2010;41:569-586.
9. Inthavong K, Ge Q, Se CMK, Yang W, and Tu JY: Simulation of sprayed particle feposition in a human nasal cavity including a nasal spray device. J Aerosol Sci. 2011; 42:100-113.
10. Shah SA, Dickens CJ, Ward DJ, Banaszek AA, George C, and Horodnik W: Design of experiments to optimize an in vitro cast to predict human nasal drug deposition. J Aerosol Med Pulm Drug Deliv. 2014;26:1-9.
11. Fry FA, and Black A: Regional deposition and clearance of particles in the human nose. J Aerosol Sci. 1973;4: 113-124.
12. Proctor DF, and Lundqvist G: Clearance of inhaled particles from the human nose. Arch Int Med. 1973;131: 132-139.
13. Schipper NGM, Verhoef JC, and Merkus FWHM: The nasal mucociliary clearance: Relevance to nasal drug delivery. Pharm Res. 1991;8:807-814.
14. Beule AG: Physiology and pathophysiology of the paranasal sinuses. GMS Curr Topics Otorhinolaryngol Head Neck Surg. 2010;9.
15. Davis SS, and Illum L: Absorption enhancers for nasal drug delivery. Clin Pharmacokinet. 2003;42:1107-1128.
16. Illum L: Nasal drug delivery-Possibilities, problems and Solutions. J Control Release. 2003;87:187-198.
17. Mistry A, Stolnik S, and Illum L: Nanoparticles for direct nose-to-brain delivery of drugs. Intl J Pharmaceut. 2009; 379:146-157.
18. Pereswetoff-Morath L: Microspheres as nasal drug delivery systems. Adv Drug Deliv Rev. 1998;29:185-194.
19. Ugwoke MI, Agu RU, Verbeke N, and Kinget R: Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives. Adv Drug Deliv Rev. 2005;57: 1640-1665.
20. Schroeter JD, Kimbell JS, and Asgharian B: Analysis of particle deposition in the turbinate and olfactory regions using a human nasal computational fluid dynamics model. J Aerosol Med. 2006;19:301-313.
21. Shi H, Kleinstreuer C, and Zhang Z: Modeling of inertial particle transport and deposition in human nasal cavities with wall roughness. J Aerosol Sci. 2007;38:398-419.
22. Schroeter JD, Garcia GJM, and Kimbell JS: Effects of surface smoothness on inertial particle deposition in human nasal models. J Aerosol Sci. 2011;42:52-63.
23. Xi J, Si X, Kim JW, and Berlinski A: Simulation of airflow and aerosol deposition in the nasal cavity of a 5-year-old child. J Aerosol Sci. 2011;42:156-173.
24. Kelly JT, Asgharian B, Kimbell JS, and Wong Ba: Particle deposition in human nasal airway replicas manufactured by different methods. Part I: Inertial regime particles. Aerosol Sci Technol. 2004;38:1063-1071.
25. Kelly JT, Asgharian B, Kimbell JS, and Wong Ba: Particle deposition in human nasal airway replicas manufactured by different methods. Part II: Ultrafine particles. Aerosol Sci Technol. 2004;38:1072-1079.
26. Garcia GJM, Tewksbury EW, Wong Ba, and Kimbell JS: Interindividual variability in nasal filtration as a function of nasal cavity geometry. J Aerosol Med Pulm Drug Deliv. 2009;22:139-155.
27. Shah SA, Berger RL, McDermott J, Gupta P, Monteith D, Connor A, and Lin W: Regional deposition of mometasone furoate nasal spray suspension in humans. Allergy Asthma Proc. 2015;36:48-57.
28. Kimbell JS, and Subramaniam RP: Use of computational fluid dynamics models for dosimetry of inhaled gases in the nasal passages. Inhal Toxicol. 2001;13:325-334.
29. Zhang Z, Kleinstreuer C, and Kim CS: Transport and uptake of MTBE and ethanol vapors in a human upper airway model. Inhal Toxicol. 2006;18:169-184.
30. Tian G, and Longest PW: Application of a new dosimetry program TAOCS to assess transient vapour absorption in the upper airways. Inhal Toxicol. 2010;22:1047-1063.
31. Tian G, and Longest PW: Development of a CFD boundary condition to model transient vapor absorption in the respiratory airways. J Biomechan Engineer. 2010;132: 051003.
32. Tian G, and Longest PW: Transient absorption of inhaled vapors into a multilayer mucus-tissue-blood system. Ann Biomed Engineer. 2010;38:517-536.
33. Hardy J, Lee S, and Wilson C: Intranasal drug delivery by spray and drops. J Pharmacy Pharmacol. 1985;37:294-297.
34. Djupesland PG, Skretting A, Winderen M, and Holand T: Breath actuated device improves delivery to target sites beyond the nasal valve. Laryngoscope. 2006;116:466-472.
35. Wang SM, Inthavong K, Wen J, Tu JY, and Xue CL: Comparison of micron-and nanoparticle deposition patterns in a realistic human nasal cavity. Resp Physiol Neurobiol. 2009;166:142-151.
36. Kimbell JS, Segal RA, Asgharian B, Wong BA, Schroeter JD, Southall JP, Dickens CJ, Brace G, and Miller FJ: Characterization of deposition from nasal spray devices using a computational fluid dynamics model of the human nasal passages. J Aerosol Med. 2007;20:59-74.
37. Bush ML, Frederick CB, Kimbell JS, and Ultman JS: A CFD PBPK hybrid model for simulating gas and vapor uptake in the rat nose. Toxicol Appl Pharmacol. 1998;150:133-145.
38. Azimi M, Longest PW, and Hindle M: Towards clinically relevant in vitro testing of locally acting nasal spray suspension products. Resp Drug Deliv Eur. 2015;1:121-130.
39. Arora D, Shah KA, Halquist MS, and Sakagami M: In vitro aqueous fluid-capacity-limited dissolution testing of respirable aerosol drug particles generated from inhaler products. Pharmaceut Res. 2010;27:786-795.
40. Quraishi MS, Jones NS, and Mason J: The rheology of nasal mucus: A review. Clin Otolaryngol Allied Sci. 1998;23: 403-413.
41. Merck: Nasonex Product Monograph. http://www.merck .ca/assets/en/pdf/products/NASONEX-PM-E.pdf. Last access: 5/1/15.
42. Guilmette RA, Wicks JD, and Wolff RK: Morphometry of human nasal airways in vivo using magnetic resonance imaging. J Aerosol Med. 1989;2:365-377.
43. Xi J, and Longest PW: Numerical predictions of submicrometer aerosol deposition in the nasal cavity using a novel drift flux approach. Intl J Heat Mass Transfer. 2008; 51:5562-5577.
44. Longest PW, Tian G, and Hindle M: Improving the lung delivery of nasally administered aerosols during noninvasive ventilation-An application of enhanced condensational growth (ECG). J Aerosol Med Pulm Drug Deliv. 2011;24: 103-118.
45. Golshahi L, Tian G, Azimi M, Son Y-J, Walenga R, Longest PW, and Hindle M: The use of condensational growth methods for efficient drug delivery to the lungs during noninvasive ventilation high flow therapy. Pharmaceut Res. 2013;30:2917-2930.
46. Shi H, Kleinstreuer C, and Zhang Z: Laminar airflow and nanoparticle or vapor deposition in a human basal cavity model. J Biomechan Engineer. 2006;128:697-706.
47. Walenga RL, Tian G, Hindle M, Yelverton J, Dodson K, and Longest PW: Variability in nose-to-lung aerosol delivery. J Aerosol Sci. 2014;78:11-29.
48. Pires AI, Fortuna A, Alves G, and Falco A: Intranasal drug delivery: How, why and what for? J Pharm Pharmaceut Sci. 2009;12:288-311.
49. Patton JS, Brain JD, Davies La, Fiegel J, Gumbleton M, Kim K-J, Sakagami M, Vanbever R, and Ehrhardt C: The particle has landed-Characterizing the fate of inhaled pharmaceuticals. J Aerosol Med Pulm Drug Deliv. 2010; 23:S71-S87.
50. Longest PW and Hindle M: Evaluation of the Respimat soft mist inhaler using a concurrent CFD and in vitro approach. J Aerosol Med Pulm Drug Deliv. 2009;22:99-112.
51. Djupesland PG: Nasal drug delivery devices: Characteristics and performance in a clinical perspective-A review. Drug Deliv Trans Res. 2013;3:42-62.
52. Djupesland PG, and Skretting A: Nasal deposition and clearance in man: Comparison of a bidirectional powder device and a traditional liquid spray pump. J Aerosol Med Pulm Drug Deliv. 2012;25:280-289.
53. Rogers D: Airway goblet cells: Responsive and adaptable front-line defenders. Eur Resp J. 1994;7:1690-1706.
54. Tarran R, Donaldson S, and Boucher RC: Rationale for hypertonic saline therapy for cystic fibrosis lung disease. Semin Resp Crit Care Med. 2007;28:295-302.
55. Jafek BW: Ultrastructure of human nasal mucosa. Laryngoscope. 1983;93:1576-1599.
56. Mestecky J, Lamm ME, Ogra PL, Strober W, Bienenstock J, McGhee JR, and Mayer L: Mucosal Immunology. Academic Press, pp. 43-64, 2005.
57. Lai SK, Wang YY, Wirtz D, and Hanes J: Microand macrorheology of mucus. Adv Drug Deliv Rev. 2009; 61:86-100.
58. Puchelle E, Zahm J, and Quemada D: Rheological properties controlling mucociliary frequency and respiratory mucus transport. Biorheology. 1986;24:557-563.
59. Cu Y, and Saltzman WM: Mathematical modeling of molecular diffusion through mucus. Adv Drug Deliv Rev. 2009;61:101-114.
60. Gulliver JS: Introduction to Chemical Transport in the Environment. Cambridge University Press, 2007.
61. Sugano K, Okazaki A, Sugimoto S, Tavornvipas S, Omura A, and Mano T: Solubility and dissolution profile assessment in drug discovery. Drug Metab Pharmacokinet. 2007; 22:225-254.
62. FDA: Nasonex Product Information. http://www.accessdata .fda.gov/drugsatfda-docs/label/2002/20762s11lbl.pdf. Last access: 5/1/15.
63. Roache PJ: Perspective: A method for uniform reporting of grid refinement studies. J Fluids Engineer. 1994;116: 405-413.
64. Gehr P, Schürch S, Berthiaume Y, HOF VI, and Geiser M: Particle retention in airways by surfactant. J Aerosol Med. 1990;3:27-43.
65. Hubal EA, Fedkiw PS, and Kimbell JS: Mass-transport models to predict toxicity of inhaled gases in the upper respiratory tract. J Appl Physiol. 1996;80:1415-1427.
66. Schroeter JD, Kimbell JS, Bonner AM, Roberts KC, Andersen ME, and Dorman DC: Incorporation of tissue reaction kinetics in a computational fluid dynamics model for nasal extraction of inhaled hydrogen sulfide in rats. Toxicol Sci. 2006;90:198-207.
67. Schroeter JD, Kimbell JS, Andersen ME, and Dorman DC: Use of a pharmacokinetic-driven computational fluid dynamics model to predict nasal extraction of hydrogen sulfide in rats and humans. Toxicol Sci. 2006;94:359-367.
68. Corley RA, Kabilan S, Kuprat AP, Carson JP, Jacob RE, Minard KR, Teeguarden JG, Timchalk C, Pipavath S, and Glenny R: Comparative risks of aldehyde constituents in cigarette smoke using transient computational fluid dynamics/physiologically based pharmacokinetic models of the rat and human respiratory tracts. Toxicol Sci. 2015:146:65-88.
69. Henning A, Schneider M, Nafee N, Muijs L, Rytting E, Wang X, Kissel T, Grafahrend D, Klee D, and Lehr C-M: Influence of particle size and material properties on mucociliary clearance from the airways. J Aerosol Med Pulm Drug Deliv. 2010;23:233-241.
70. Buttini F, Miozzi M, Balducci AG, Royall PG, Brambilla G, Colombo P, Bettini R, and Forbes B: Differences in physical chemistry and dissolution rate of solid particle aerosols from solution pressurised inhalers. Intl J Pharmaceut. 2014;465:42-51.
71. Bur M, Huwer H, Muys L, and Lehr C-M: Drug transport across pulmonary epithelial cell monolayers: Effects of particle size, apical liquid volume, and deposition technique. J Aerosol Med Pulm Drug Deliv. 2010;23:119-127.
72. Illum L: Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharmaceut Sci. 2000;11:1-18.
73. Hanson LR, and Frey WH: Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci. 2008;9:S5.
74. Suman JD, Laube BL, and Dalby R: Validity of in vitro tests on aqueous spray pumps as surrogates for nasal deposition, absorption, and biologic response. J Aerosol Med. 2006;19:510-521.
75. Li BV, Jin F, Lee SL, Bai T, Chowdhury B, Caramenico HT, and Conner DP: Bioequivalence for locally acting nasal spray and nasal aerosol products: Standard development and generic approval. AAPS J. 2013;15:875-883.